6533b82cfe1ef96bd128f534
RESEARCH PRODUCT
Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study
Marco D'amelioGiulia VazzolerPaolo RagonesePaolo AridonMaria Antonietta MazzolaVincenzina Lo ReGiuseppe SalemiGiovanni SavettieriSabrina RealmutoMarianna Lo ReSimona Alessisubject
AdultMaleRiskmedicine.medical_specialtyMultiple SclerosisPopulationlcsh:RC346-429Cohort StudiesYoung Adult03 medical and health sciences0302 clinical medicineNeoplasmsInternal medicinemedicineHumansMultiple sclerosiCancer; Cohort study; Immunosuppressant; Multiple sclerosis; Treatment; Neurology (clinical)Prospective cohort studyeducationlcsh:Neurology. Diseases of the nervous systemCancerImmunosuppressanteducation.field_of_studybusiness.industryIncidenceMultiple sclerosisCancerRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTreatment030220 oncology & carcinogenesisRelative riskCohortFemaleNeurology (clinical)Cohort studybusinessImmunosuppressive Agents030217 neurology & neurosurgeryResearch ArticleCohort studydescription
Abstract Background The association between multiple sclerosis (MS) and cancer has long been investigated with conflicting results. Several reports suggest an increased cancer risk among MS patients treated with immunosuppressant (IS) drugs. Methods We performed a cohort study including MS patients recruited at the Neurological Department of the University of Palermo. Mean follow-up period was ten years for the whole cohort. We calculated cancer incidence among patients treated with IS. Incidence rates were compared in the cohort by calculating the relative risk according to length and dose of exposure to IS. Cancer incidence among MS patients was compared to cancer incidence in the general population of Sicily in similar age groups. Results On an overall cohort of 531 MS patients (346 women and 185 men) exposed to IS, we estimated a crude incidence rate for cancer of 2.26% (2.02% in women, 2.7% in men). Cancer risk was higher compared to rates observed among an equal number of patients not exposed to IS, and to the risk in the general population in Sicily at similar age groups (adjusted HR: 11.05; CI 1.67–73.3; p = 0.013). Conclusion The present study showed a higher cancer risk in MS patients associated only to previous IS exposure. Studies on long-term outcomes are essential to evaluate the possibility that treatment options that need to be considered for a long time-period may modify risk for life threatening diseases.
year | journal | country | edition | language |
---|---|---|---|---|
2017-08-01 | BMC Neurology |